Sinovac Biotech Ltd. (SVA) Fair Value 2026

SVA · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.9 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-28, Sinovac Biotech Ltd. (SVA) trades at $6.47. QOC: 2.9/10. Value Trap Risk: 0/100 (SAFE). 1/13 models active.

Key Facts

Ticker
SVA
Price
$6.47
Quality Score
2.9/10
Value Trap Risk
0/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 2.9/10 signals weak fundamentals

What Fair Value Does Each Model Give SVA?

1 Intrinsic Value Models vs. Current Price ($6.47)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $6.47 -0.0%

All Models Active

All 1 models are displayed above.

What Is Sinovac Biotech Ltd. (SVA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Sinovac Biotech Ltd.'s intrinsic value is estimated at a median $6.47, showing conflicting signals at the current price of $6.47. While the median implied return is -0.0%, model disagreement is elevated with a gap of +0.0% between the most bullish and bearish estimates.

What Do the Models Say About SVA?

1 of 13 models are currently active for SVA. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does SVA Rank in Pharmaceutical Preparations?

Among 1 Pharmaceutical Preparations stocks, SVA ranks #1 by Quality of Company score. CirclFi's QOC score of 2.9/10 evaluates 32 fundamental signals. A score of 2.9 signals below-average fundamentals.

Sinovac Biotech Ltd.'s positioning within the Pharmaceutical Preparations segment means that R&D productivity ratio plays an outsized role in fundamental analysis. The sector's unique characteristics — including regulatory pathway clarity — shape both the opportunity set and risk profile.

Is SVA a Value Trap?

CirclFi's Value Trap algorithm assigns SVA a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Sinovac Biotech Ltd.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Sinovac Biotech Ltd. scores 2.9 out of 10 on our 32-signal quality assessment, a weak rating that exhibits fundamental weaknesses that warrant careful scrutiny. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SVA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SVA's 1 active models, average confidence is 32%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Sinovac Biotech Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Other Stocks Have a Similar Quality Score to SVA?

7 companies across all industries closest to SVA’s Quality of Company score of 2.9/10.

CLOWCloudweb, Inc.QOC 2.9FNVFranco-Nevada CorporationQOC 2.9PETZTDH Holdings, Inc.QOC 2.9SVMSilvercorp Metals Inc.QOC 2.9GFIGold Fields LimitedQOC 2.9YAASYouxin Technology LtdQOC 2.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CLOW · FNV · PETZ · SVM · GFI · YAAS · NVDA

What Else Do Investors Ask About Sinovac Biotech Ltd.’s Valuation?

What is Sinovac Biotech Ltd.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Sinovac Biotech Ltd. (SVA). The Quality of Company score is 2.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SVA overvalued or undervalued right now?

At $6.47, 0 of 1 active models suggest SVA may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Sinovac Biotech Ltd.'s business model in Pharmaceutical Preparations.

What does a Quality of Company score of 2.9 mean for SVA?

Sinovac Biotech Ltd.'s QOC of 2.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on SVA?

CirclFi analyzes SVA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is SVA a value trap in 2026?

Sinovac Biotech Ltd.'s Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Sinovac Biotech Ltd. (SVA) a Quality of Company score of 2.9/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/SVA/ · Methodology
Primary sources for this SVA valuation
  • Financial statements: Sinovac Biotech Ltd. 10-K and 10-Q filings on SEC EDGAR (CIK 0001084201) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SVA as of ; valuations recomputed .